Physician profile
Manish Sharma
NPI 1912943218
$7,964.73
in general payments reported to CMS, 2019-2025
23 companies · $66.85 in 2025
The $66.85 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,498 · 2020: $532 · 2021: $633 · 2022: $566 · 2023: $380 · 2024: $2,290 · 2025: $66.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531 · Travel and Lodging: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.19 |
| Travel and Lodging | $1,205.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,270.86 | 2019-2024 | Watchman Access System, Watchman Flx, Resonate El Icd Vr |
| Medtronic Vascular, INC. | $1,618.13 | 2019-2020 | |
| Heartflow, INC. | $689.94 | 2020-2024 | Ffrct |
| Novartis Pharmaceuticals Corporation | $492.19 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $323.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $304.98 | 2019-2023 | Farxiga |
| Amgen INC. | $265.84 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.72 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $247.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $239.80 | 2019-2022 | |
| Pfizer INC. | $215.60 | 2019-2020 | |
| Atricure, INC. | $162.97 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $141.27 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $140.00 | 2022 | |
| Cardiovascular Systems INC. | $128.84 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $128.55 | 2019 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Edwards Lifesciences Corporation | $81.07 | 2024 | Sapien 3 Ultra Resilia |
| Kestra Medical Technology Services, INC. | $48.92 | 2024 | Assure Wcd |
| Chiesi USA, INC. | $35.63 | 2019-2022 | |
| Shockwave Medical, INC | $32.02 | 2025 | |
| Medtronic, INC. | $17.47 | 2025 | Ffrangio |
| Novo Nordisk INC | $17.36 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.